证券代码：688062 证券简称：迈威生物 公告编号：2025-061 迈威（上海）生物科技股份有限公司 关于 2025 年度第一期定向科技创新债券发行结果的 公告 本 期 发 行 定 向 科 技 创 新 债 券 的 相 关 文 件 已 在 中 国 货 币 网 （www.chinamoney.com.cn）、上海清算所网站（www.shclearing.com.cn）刊登。 经通过"信用中国"网站（www.creditchina.gov.cn）核查，截至本公告日， 公司不属于失信责任主体。 特此公告。 2025 年 9 月 11 日，公司收到交易商协会出具的《接受注册通知书》（中市 协注〔2025〕PPN310 号），交易商协会决定接受公司科技创新债券注册，注册 基础品种为定向债务融资工具，注册金额为 5 亿元，注册额度自通知书落款之日 起 2 年内有效，在注册有效期内可分期定向发行科技创新债券。 公司 2025 年度第一期定向科技创新债券于 2025 年 10 月 15 日完成发行，募 集资金已于 2025 年 10 月 16 日到账。现将发行结果公告如下： | 债券全称 | 迈威（上海）生物科技股份 有限 ...

Core Insights - The article highlights the active engagement of private equity firms in conducting research on listed companies, with a total of 2712 private equity firms researching 1490 stocks, resulting in 18,500 research instances since the beginning of the second half of the year [1][4]. Group 1: Private Equity Research Activity - The most active private equity firms include Shenzhen Shangcheng Asset Management with 291 research instances and Guangdong Zhengyuan Private Equity with 217 instances, covering 271 and 199 stocks respectively [2][1]. - Other notable firms include Qingli Investment and Pankin Investment, with 143 and 142 research instances respectively, both covering 130 stocks [1][2]. - A total of 45 private equity firms conducted between 50 to 100 research instances during the same period [1]. Group 2: Focus Areas of Research - The TMT (Technology, Media, and Telecommunications) sector is a primary focus, with 384 stocks researched, accounting for 25.77% of the total [4]. - Within the TMT sector, the electronics and computer industries had 207 and 118 stocks researched respectively, while the telecommunications and media sectors had fewer stocks at 38 and 21 [4]. - Other sectors with significant research interest include machinery and pharmaceuticals, with 200 and 179 stocks researched respectively [5]. Group 3: Market Performance - The average increase in the 31 Shenwan primary industry indices since the beginning of the second half of the year is 15.13% [5]. - Specific indices in the TMT sector, such as telecommunications, electronics, and power equipment, have seen increases exceeding 40% [5]. - The machinery and basic chemicals sectors also performed well, with increases of 24.16% and 16.47% respectively [5]. Group 4: Stock Performance - Among the 1490 stocks researched, 558 stocks saw price increases between 0%-20%, while 406 stocks increased between 20%-50%, together making up 64.7% of the total [7]. - A total of 44 stocks experienced price increases exceeding 100%, and 154 stocks increased between 50%-100% [7]. - Five stocks attracted over 100 private equity firms for research, including Maiwei Biotech and Mindray Medical, with respective price increases of 66.97% and 3.14% [8].

10月16日，迈威生物盘中上涨2.18%，截至10:16，报48.25元/股，成交2.26亿元，换手率2.34%，总市值 192.81亿元。 资金流向方面，主力资金净流入781.04万元，特大单买入1292.29万元，占比5.71%，卖出1211.61万元， 占比5.35%；大单买入5781.67万元，占比25.53%，卖出5081.31万元，占比22.44%。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、抗癌药物、抗 癌治癌、创新药、眼科概念等。 截至6月30日，迈威生物股东户数1.79万，较上期增加11.66%；人均流通股11379股，较上期减少 10.44%。2025年1月-6月，迈威生物实现营业收入1.01亿元，同比减少12.43%；归母净利润-5.51亿元， 同比减少23.90%。 机构持仓方面，截止2025年6月30日，迈威生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股474.26万股，为新进股东。兴全合润混合A（163406）位居第五大流通股东，持股339.00 万股，为新进股东。鹏华医药科技股票A（001230）位居第六大流通股东，持股 ...

Core Viewpoint - The innovative drug concept stocks experienced a significant surge in early trading on October 15, with several companies reaching their daily price limits and notable increases in stock prices [1]. Group 1: Stock Performance - Angli康 reached the daily limit up, indicating strong investor interest [1]. - Guangshengtang saw a rise of over 10%, with a notable increase of 14.41% in its stock price [2]. - Other companies such as Saili Medical, Shutaishen, Rongchang Bio, and Lianhuan Pharmaceutical also experienced substantial gains, contributing to the overall positive trend in the innovative drug sector [1]. Group 2: Notable Stock Increases - Guangshengtang (300436) reported a stock increase of 116.94%, with a rise of 14.41% [2]. - Pinlikang (002940) increased by 41.20%, with a rise of 10.01% [2]. - Saili Medical (603716) saw a 27.12% increase, with an 8.35% rise [2]. - Shutaishen (300204) experienced a 34.77% increase, with a 7.88% rise [2]. - Jimin Health (603222) rose by 10.64%, with a 6.72% increase [2]. - Lianhuan Pharmaceutical (600513) increased by 20.21%, with a 6.37% rise [2]. - Rongchang Bio (688331) saw a 97.06% increase, with a 6.31% rise [2]. - Zhendong Pharmaceutical (300158) increased by 6.95%, with a 5.95% rise [2]. - Kangchen Pharmaceutical (035500) rose by 48.68%, with a 4.91% increase [2]. - Maiwei Niwu-U (688062) saw a 46.58% increase, with a 4.86% rise [2].

Core Viewpoint - The A-share market is experiencing a rebound, particularly in the innovative drug sector, with significant inflows into the ETF focused on this area, indicating growing investor interest and confidence in the sector [1][5]. Group 1: Market Performance - As of 10:23 on October 15, the Kexin Innovative Drug ETF (589120) saw a rise of nearly 3%, currently up over 2% [1]. - The ETF recorded a net inflow of over 6 million yuan for the day, with a cumulative inflow of over 56 million yuan in the past 10 days [1]. Group 2: Stock Performance - Most component stocks of the Kexin Innovative Drug ETF experienced gains, with Rongchang Bio rising over 6%, Maiwei Bio over 5%, and several others including Ailis and Borui Pharma rising over 3% [3]. - The top-performing stocks by estimated weight include Baiji Shenzhou (9.89%), Ailis (8.60%), and Baili Tianheng (8.16%) [4]. Group 3: Industry Developments - Rongchang Bio announced that its innovative drug, Tai Tasi Pi, for treating primary immunoglobulin A nephropathy, has received acceptance for market application from the National Medical Products Administration (NMPA) [5]. - The upcoming European Society for Medical Oncology (ESMO) conference from October 17 to 21 in Berlin is anticipated to showcase new data on domestic innovative drugs, which could create new business development (BD) opportunities [5][6]. Group 4: Regulatory and Market Insights - Analysts suggest that the impact of tariff policies on China's pharmaceutical industry is limited, with the market having already priced in the effects of drug tariffs [5]. - The number of overseas BD transactions by Chinese innovative drug companies is expected to continue growing, with significant increases in both the number and total transaction value from 2022 to 2025 [6].

资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品99.91%，提供劳务 0.09%。 10月15日，迈威生物盘中上涨2.05%，截至10:03，报45.33元/股，成交1.10亿元，换手率1.20%，总市值 181.14亿元。 资金流向方面，主力资金净流入607.26万元，特大单买入613.51万元，占比5.57%，卖出235.49万元，占 比2.14%；大单买入3098.47万元，占比28.13%，卖出2869.24万元，占比26.05%。 迈威生物今年以来股价涨124.41%，近5个交易日跌7.72%，近20日跌9.74%，近60日涨46.94%。 今年以来迈威生物已经5次登上龙虎榜，最近一次登上龙虎榜为9月2日。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、抗癌治癌、抗 癌药物、眼科概念、创新药等。 截至6月30日，迈威生物股东户 ...

Core Viewpoint - The restoration of the giant landmark "Serve the People" in Hami, Xinjiang, has garnered significant public attention and government response, highlighting the importance of preserving historical and cultural heritage [1][5]. Group 1: Historical Significance - The five giant landmarks in Hami serve as historical witnesses to the People's Air Force's training history, established in the 1960s to guide pilots during their training in the vast Gobi Desert [3][4]. - The phrase "Serve the People" measures 50 meters in length and width, acting as a crucial navigational aid for pilots in an era without satellite positioning [3][4]. Group 2: Community Involvement - A history enthusiast, Lu Yao, discovered damage to the landmark while reviewing satellite images and took the initiative to repair it with the help of local friends and volunteers, transporting 20 tons of similar gravel over nine days [4][5]. - The restoration efforts were supported by Changguang Satellite Technology Co., which provided satellite imaging to document the repair process [5]. Group 3: Government Response - Following the viral video of the restoration, Hami's government organized a meeting to discuss ongoing protection measures for the landmarks, involving multiple departments [6][7]. - The Cultural, Sports, Radio, Television, and Tourism Bureau of Hami has included the giant landmarks in the fourth cultural relics census and plans to seek expert evaluation for better protection strategies [7].

Core Viewpoint - The company Insilico Medicine is making a third attempt to list on the Hong Kong Stock Exchange after two previous failed attempts in June 2023 and March 2024, with recent developments indicating regulatory scrutiny regarding its prior failed listings [1] Group 1: Business Model and Financial Performance - Insilico Medicine focuses on AI-driven drug development, with three main business segments: drug discovery and pipeline development, software solutions, and other discoveries related to non-pharmaceutical fields, with drug development accounting for over 90% of revenue [2] - The company's revenue from 2022 to 2024 shows significant growth, with figures of $30.147 million, $51.180 million, and $85.834 million respectively, while net losses for the same period were $220 million, $210 million, and $17.1 million, totaling approximately $450 million in cumulative losses [2] - The company relies heavily on a few major clients, with revenue from the top five clients constituting 90.6%, 94.1%, and 94.4% of total revenue from 2022 to 2024 [2] Group 2: Product Pipeline and R&D - The fastest progressing candidate drug is Rentosertib (ISM001-055), aimed at treating idiopathic pulmonary fibrosis, which has gained attention due to its AI-assisted discovery [3] - Insilico Medicine has established over 30 self-developed pipelines, with a diversified layout across various therapeutic areas, including fibrosis, inflammatory bowel disease, oncology, metabolic diseases, and neurological disorders [4] - The company has announced a strategic cooperation agreement related to antibody-drug conjugates (ADC) with other biotech firms, indicating its intent to expand its product offerings [4] Group 3: R&D Expenditure and Challenges - R&D expenditures from 2022 to 2024 were $78.18 million, $97.34 million, and $91.90 million, with third-party contracting costs consistently exceeding 60% of R&D spending [5] - The company has a total of 308 employees, with 241 dedicated to R&D, indicating a smaller scale compared to competitors like Zai Lab, which has over 500 R&D staff [4] Group 4: Competitive Landscape and Funding - The AI drug development sector is becoming increasingly competitive, with major players like Baidu and Tencent entering the market, highlighting the importance of financing for startups like Insilico Medicine [6] - Insilico Medicine completed a $123 million Series E funding round in June 2023, led by several investment firms, emphasizing the urgency to commercialize its Rentosertib drug to maintain its industry position [7]

Group 1 - Jiang Dongdong, the Secretary of the Taizhou Municipal Committee, is leading a招商攻势 (investment promotion campaign) in the Yangtze River Delta, focusing on high-tech companies to enhance economic development and project implementation [1] - The campaign's first stop was Shanghai, where Taizhou aims to deepen industrial cooperation and innovation with local companies, emphasizing the integration with Shanghai's resources [1][2] - Taizhou is building a modern industrial system marked by "Dahai New Morning," focusing on strengthening health, marine engineering, and high-tech shipbuilding industries, while also developing strategic emerging industries like new materials and new energy [2] Group 2 - The investment promotion targets "technology new forces," with companies like Yuzhu Technology and Lingban Technology being key focuses, as they represent significant advancements in their respective fields [2] - Jiang Dongdong observed demonstrations at Yuzhu Technology, expressing interest in collaborating on technology transfer and applications in industrial sectors, particularly in robotics [2] - At Lingban Technology, Jiang experienced the latest AR products and emphasized the importance of integrating AI technology with traditional industries for digital transformation in Taizhou [2] Group 3 - Recently, Zhiyuan Innovation partnered with Huguang Automotive Electric Co., Ltd. to establish a comprehensive embodied intelligence company, indicating a strategic move towards robotics in Taizhou [3] - Jiang Dongdong visited Zhiyuan Innovation, discussing the potential for establishing a robotics production base in Taizhou and encouraging collaboration with upstream and downstream enterprises [3]

Core Insights - Shanghai is leading the nation in the innovation of pharmaceuticals and medical devices, with 30 approved domestic Class I innovative drugs from 2021 to September 2025, accounting for 17% of the national total [1] - The biopharmaceutical industry in Shanghai reached a scale of 500.57 billion yuan in the first half of this year, with expectations to surpass 1 trillion yuan for the full year [2] - Shanghai's License-out transactions for innovative drugs reached 38 in 2024, representing 35% of the national total, with a transaction value of 30.7 billion USD, accounting for 47% of the national total [3] Industry Growth - The biopharmaceutical industry in Shanghai has shown consistent growth, increasing from 761.71 billion yuan in 2021 to an estimated 984.70 billion yuan in 2024, with a compound annual growth rate of 8.94% [2] - By the end of 2024, Shanghai is expected to have 2,183 biopharmaceutical enterprises, covering manufacturing, services, and wholesale [2] - Shanghai has seen 46 companies go public from 2021 to 2024, with 4 new listings in 2023 alone [2] International Recognition - Since 2021, 9 drugs have been approved in international markets such as the US and Japan, indicating the global recognition of Shanghai's innovative capabilities [3] - Major international pharmaceutical and medical device companies have established headquarters or R&D centers in Shanghai, with 19 out of the top 20 in each category present [2] Policy Support - Shanghai has implemented various policies to support the biopharmaceutical industry, including regulations and action plans focused on synthetic biology, cell and gene therapy, and AI in medicine [4] - A biopharmaceutical industry mother fund with a total scale of 22.5 billion yuan has been established, along with a 10 billion yuan merger fund targeting strategic acquisitions in traditional Chinese medicine, vaccines, and high-end medical devices [4] - From 2021 to 2024, Shanghai's biopharmaceutical sector has secured 238.37 billion yuan in financing, ranking among the top in the country [4] Innovation Ecosystem - Shanghai has built a comprehensive innovation ecosystem that spans from research to clinical application, providing new momentum for high-quality development in the biopharmaceutical industry [5]